SRRK

Scholar Rock Holding Corp. 10-Q Summary: Q2 2025

Business Context and Reporting Period

Scholar Rock Holding Corp. (SRRK) is a late-stage biopharmaceutical company focused on developing monoclonal antibodies that target growth factors. The primary product candidate is apitegromab, a muscle-targeted treatment for Spinal Muscular Atrophy (SMA). The company also maintains a pipeline including SRK-181 (oncology), SRK-439 (neuromuscular), and others. This report covers the quarterly period ended June 30, 2025.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no product revenue to date.

Material Changes vs. Prior Period

• Expense Surge: Total operating expenses increased by 88.4% in Q2 2025 compared to Q2 2024. This was driven by a 190.3% increase in General and Administrative (G&A) expenses and a 47.3% increase in Research and Development (R&D) expenses.
• Leadership Transition Costs: A significant portion of the expense increase (approximately $13.0 million in one-time charges) is attributed to the management transition in April 2025, including severance and equity award modifications.
• Liquidity Position: Total cash, cash equivalents, and marketable securities decreased by approximately $142.3 million year-over-year, primarily due to higher operating burn and reduced marketable securities balances.
• Debt Refinancing: In February 2025, the company amended its loan agreement with Oxford Finance, extending the maturity date to 2030 and increasing total borrowing capacity to $200 million (with $50 million currently drawn).

Guidance, Outlook, and Risks

• Regulatory Milestones: The FDA has accepted the Biologics License Application (BLA) for apitegromab for SMA under priority review, with a PDUFA target action date of September 22, 2025. A Marketing Authorisation Application (MAA) was validated by the EMA in March 2025.
• Commercialization Plan: If approved, the company expects to launch commercially in the U.S. in Q4 2025 and in Europe in 2026.
• Clinical Updates:
  • EMBRAZE Trial: Positive top-line data announced in June 2025 showed apitegromab preserved lean mass in patients with obesity on tirzepatide therapy.
  • SRK-181: Phase 1 DRAGON trial completed in June 2025 with encouraging responses in anti-PD-1 resistant cancers.
  • OPAL Trial: Planned initiation in Q3 2025 for SMA patients under two years of age.
• Liquidity Outlook: Management believes current resources ($295 million) are sufficient to fund operations into 2027. However, additional capital will be required for full commercialization.
• Risk Factors: Key risks include the uncertainty of FDA/EMA approval, the ability to build a commercial infrastructure, reliance on third-party manufacturers, and the potential for increased costs due to inflation or geopolitical instability. The company will transition from a "smaller reporting company" to a "large accelerated filer" effective December 31, 2025.

Investor Verification Checklist

• Approval Timeline: Verify the status of the FDA PDUFA date (Sept 22, 2025) and any potential delays or requests for additional data.
• Burn Rate: Assess the sustainability of the current cash burn rate (~$155 million operating cash outflow for H1 2025) against the $295 million liquidity runway.
• One-Time Costs: Confirm the extent of the $13.0 million in one-time leadership transition charges to normalize future G&A expense expectations.
• Debt Covenants: Review the terms of the amended Oxford Finance loan agreement, specifically the milestone triggers for the remaining $150 million in tranches.
• Commercial Readiness: Evaluate the company's progress in hiring sales and marketing personnel and establishing distribution channels for a potential Q4 2025 launch.